Oral bisphosphonates are the most commonly prescribed antiresorptive drugs for the treatment of osteoporosis. However, there are several adverse effects associated with oral bisphosphonates including the bisphosphonate related osteonecrosis of the jaw (BRONJ). With a better understanding of this side effect, reported incidences for BRONJ in oral bisphosphonate users have increased in time. The pathogenesis of BRONJ has not been well determined. Several risk factors such as dentoalveolar surgery, therapy duration, and concomitant steroid usage have been linked to BRONJ. Conservative and surgical methods can be preferred in the treatment. Preventative measures are of great importance for the patients at high risk. In this paper, osteonecrosis of the jaw secondary to oral bisphosphonates was reviewed in order to increase awareness as well as to renew the current knowledge.
Keyphrases
- risk factors
- minimally invasive
- ejection fraction
- emergency department
- newly diagnosed
- postmenopausal women
- prognostic factors
- mesenchymal stem cells
- bone mineral density
- percutaneous coronary intervention
- combination therapy
- body composition
- coronary artery bypass
- atrial fibrillation
- cell therapy
- acute coronary syndrome